Phase I study of PF-03446962, a fully human mAb against ALK 1, a TGFβ receptor involved in tumor angiogenesis.

被引：3
|
作者：
Goff, L. W.
Cohen, R. B.
Berlin, J.
Noberasco, C.
Borghaei, H.
Gallo-Stampino, C.
Wang, E.
Lowe, D. Hu
Levin, W. J.
De Braud, F. G.
机构：
[1] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[2] Univ Penn, Philadelphia, PA 19104 USA
[3] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[4] European Inst Oncol, Milan, Italy
[5] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[6] Pfizer Oncol, Milan, Italy
[7] Pfizer Oncol, La Jolla, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.3009
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3009
引用
收藏
页数：1
相关论文
共 45 条
  • [21] A phase I dose-escalation study of weekly IMC-A12, a fully human insulin like growth factor-1 receptor (IGF-IR) IgG1 monoclonal antibody (Mab), in patients (pts) with advanced cancer
    Higano, C.
    Gordon, M.
    LoRusso, R.
    Fox, F.
    Katz, T.
    Roecker, J.
    Rowinsky, E.
    Youssoufian, H.
    EJC SUPPLEMENTS, 2006, 4 (12): : 195 - 195
  • [22] PF-06952229, a selective TGF-β-R1 inhibitor: preclinical development and a first-in-human, phase I, dose-escalation study in advanced solid tumors
    Yap, T. A.
    Choudhury, A. D.
    Hamilton, E.
    Rosen, L. S.
    Stratton, K. L.
    Gordon, M. S.
    Schaer, D.
    Liu, L.
    Zhang, L.
    Mittapalli, R. K.
    Zhong, W.
    Soman, N.
    Tolcher, A. W.
    ESMO OPEN, 2024, 9 (09)
  • [23] Phase I study of AMG 479, a fully human monoclonal antibody against the type 1 insulin-like growth factor receptor (IGF-1R), in Japanese patients (pts) with advanced solid tumors
    Doi, T.
    Fuse, N.
    Yoshino, T.
    Murakami, H.
    Yamamoto, N.
    Boku, N.
    Otani, S.
    Shibayama, K.
    Takubo, T.
    Elwyn, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [24] Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors
    Murakami, Haruyasu
    Doi, Toshihiko
    Yamamoto, Nobuyuki
    Watanabe, Junichiro
    Boku, Narikazu
    Fuse, Nozomu
    Yoshino, Takayuki
    Ohtsu, Atsushi
    Otani, Satoru
    Shibayama, Kazuhiro
    Takubo, Takatoshi
    Loh, Elwyn
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (03) : 407 - 414
  • [25] Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors
    Haruyasu Murakami
    Toshihiko Doi
    Nobuyuki Yamamoto
    Junichiro Watanabe
    Narikazu Boku
    Nozomu Fuse
    Takayuki Yoshino
    Atsushi Ohtsu
    Satoru Otani
    Kazuhiro Shibayama
    Takatoshi Takubo
    Elwyn Loh
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 407 - 414
  • [26] A phase I first-in-human study of REGN910 (SAR307746), a fully human and selective angiopoietin-2 (Ang2) monoclonal antibody (MAb), in patients with advanced solid tumor malignancies.
    Papadopoulos, Kyriakos P.
    Sahebjam, Solmaz
    Kelley, Robin Katie
    Tolcher, Anthony W.
    Razak, Albiruni R. A.
    Patnaik, Amita
    Bedard, Philippe L.
    Arcos, Rebecca
    Adriaens, Lieve
    Brownstein, Carrie M.
    Lowy, Israel
    Gao, Bo
    DiCioccio, A. Thomas
    Trail, Pamela
    Siu, Lillian L.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [27] IMC-18F1, a recombinant human monoclonal antibody (MAb) against the vascular endothelial growth factor receptor-1 (VEGFR-1), in the treatment of patients (pts) with advanced solid malignancies: A Phase 1 study
    Krishnamurthi, S.
    Goncalves, P. H. B.
    Fox, F.
    Hall, N.
    Rowinsky, E.
    Schwartz, J.
    Youssoufian, H.
    LoRusso, P.
    EJC SUPPLEMENTS, 2008, 6 (12): : 127 - 128
  • [28] A phase I dose-escalation study of weekly IMC-1121B, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR2) IgG1 monoclonal antibody (Mab), in patients (pts) with advanced cancer.
    Camidge, D. R.
    Eckhardt, S. G.
    Diab, S.
    Gore, L.
    Chow, L.
    O'Bryant, C.
    Temmer, E.
    Ervin-Haynes, A.
    Katz, T.
    Fox, F.
    Cohen, R. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 128S - 128S
  • [29] Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1 (vol 25, pg 1390, 2007)
    Tolcher
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (29) : 4701 - 4701
  • [30] A phase I, first in man study of weekly IMC-A12, a fully human insulin like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid tumors
    Higano, C. S.
    Yu, E. Y.
    Whiting, S. H.
    Gordon, M. S.
    LoRusso, P.
    Fox, F.
    Katz, T. L.
    Roecker, J. M.
    Schwartz, J. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345